Sorafenib Plus Ixabepilone as First-Line Treatment of...

  • Main
  • 2016 / 2
  • Sorafenib Plus Ixabepilone as First-Line Treatment of...
Clinical Breast Cancer 2016 / 2

Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial

Yardley, Denise A., Dickson, Natalie, Drosick, David, Earwood, Chris, Inhorn, Roger, Murphy, Patrick, Hainsworth, John D.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Clinical Breast Cancer
DOI:
10.1016/j.clbc.2016.02.003
Date:
February, 2016
File:
PDF, 392 KB
english, 2016
Conversion to is in progress
Conversion to is failed